These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
359 related articles for article (PubMed ID: 9677975)
21. [The hierarchization of the prognostic factors in uveal malignant melanoma]. Călugăru M; Mera M; Călugăru D Oftalmologia; 2000; 50(1):30-4. PubMed ID: 11021104 [TBL] [Abstract][Full Text] [Related]
22. Update on posterior uveal melanoma: treatment of the eye and emerging strategies in the prognosis and treatment of metastatic disease. Shildkrot Y; Wilson MW Curr Opin Ophthalmol; 2009 Nov; 20(6):504-10. PubMed ID: 19644367 [TBL] [Abstract][Full Text] [Related]
23. Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma. Mäkitie T; Carpén O; Vaheri A; Kivelä T Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2442-9. PubMed ID: 11581181 [TBL] [Abstract][Full Text] [Related]
24. Developments in the management of uveal melanoma. Damato B Clin Exp Ophthalmol; 2004 Dec; 32(6):639-47. PubMed ID: 15575836 [TBL] [Abstract][Full Text] [Related]
26. Metastatic melanoma in the eye and orbit. Zografos L; Ducrey N; Beati D; Schalenbourg A; Spahn B; Balmer A; Othenin-Girard CB; Chamot L; Egger E Ophthalmology; 2003 Nov; 110(11):2245-56. PubMed ID: 14597536 [TBL] [Abstract][Full Text] [Related]
27. HLA Class I and II genotype in uveal melanoma: relation to occurrence and prognosis. Maat W; Haasnoot GW; Claas FH; Schalij-Delfos NE; Schreuder GM; Jager MJ Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):3-6. PubMed ID: 16384937 [TBL] [Abstract][Full Text] [Related]
28. [Immunoglobulins M, G and A as prognostic criteria of the treatment outcome in uveal melanoblastoma]. Kotelianskiĭ EO Oftalmol Zh; 1989; (2):104-7. PubMed ID: 2755651 [TBL] [Abstract][Full Text] [Related]
29. Cytogenetics of uveal melanoma: a 7-year clinical experience. Damato B; Duke C; Coupland SE; Hiscott P; Smith PA; Campbell I; Douglas A; Howard P Ophthalmology; 2007 Oct; 114(10):1925-31. PubMed ID: 17719643 [TBL] [Abstract][Full Text] [Related]
30. [Management of a melanoma of the choroid or ciliary body]. de Jong PT Ned Tijdschr Geneeskd; 1987 Mar; 131(11):439-43. PubMed ID: 3561548 [No Abstract] [Full Text] [Related]
32. Current alternatives in the management of posterior uvea melanomas. Shields JA; Shields CL; Shah P; DePotter P Trans Pa Acad Ophthalmol Otolaryngol; 1990; 42():938-44. PubMed ID: 2084990 [TBL] [Abstract][Full Text] [Related]
33. Eye-wall resection. Char DH; Miller T; Crawford JB Trans Am Ophthalmol Soc; 2000; 98():153-9; discussion 159-61. PubMed ID: 11190019 [TBL] [Abstract][Full Text] [Related]
37. Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Mäkitie T; Summanen P; Tarkkanen A; Kivelä T Invest Ophthalmol Vis Sci; 1999 Oct; 40(11):2471-80. PubMed ID: 10509639 [TBL] [Abstract][Full Text] [Related]
38. Current management of posterior uveal melanoma. Shields JA; Shields CL Mayo Clin Proc; 1993 Dec; 68(12):1196-200. PubMed ID: 8246622 [TBL] [Abstract][Full Text] [Related]
39. [Characteristics of the immune status of patients with uveal melanoma during the performance of organ-preserving treatment]. Maletskiĭ AP; Vit VV; Vanichkin AA Oftalmol Zh; 1989; (6):341-6. PubMed ID: 2622598 [TBL] [Abstract][Full Text] [Related]
40. Conservation of eyes with choroidal melanoma by a multimodality approach to treatment: an audit of 1632 patients. Damato B; Lecuona K Ophthalmology; 2004 May; 111(5):977-83. PubMed ID: 15121377 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]